Cancer Programs
While an estimated 60% of global cancer cases occur in low- and middle-income countries, only 5% of global spending on cancer is directed to these countries.* Opening access to treatment has the potential to save thousands of lives today and in years to come.
Diseases we treat
- Chronic myeloid leukemia (CML)
- Anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC)
- Dermatofibrosarcoma protuberans (DFSP)
- Gastrointestinal stromal tumor (GIST)
- Hypereosinophilic syndrome (HES)
- Chronic eosinophilic leukemia (CEL)
- Myelodysplastic/myeloproliferative diseases (MDS/MPD)
- ROS1 non-small cell lung cancer
- Systemic mastocytosis (SM)
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- Renal cell carcinoma (RCC)
- Pancreatic neuroendocrine tumors (pNET)
Disease and Treatment Matrix (as of 2019)
| DISEASE | ||||||||||
| CML | GIST | RCC | NSCLC | pNET | ALL | MDS/MPD | SM | HES/CEL | DSFP | |
| Imatinib (Glivec®) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
| Nilotinib (Tasigna®) | ✓ | |||||||||
| Dasatinib (Sprycel®) | ✓ | ✓ | ||||||||
| Bosutinib (Bosulif®) | ✓ | |||||||||
| Ponatinib (Iclusig®) | ✓ | ✓ | ||||||||
| Sunitinib malate (Sutent®) | ✓ | ✓ | ✓ | |||||||
| Crizotinib (Xalkori®) | ✓ | |||||||||
| Temsirolimus (Torisel®) | ✓ | |||||||||
| Axitinib (Inlyta®) | ✓ | |||||||||
Collaboration is Key
From the start, we’ve carried out our work in partnership with people and organizations around the world. We know that collaboration is critical to our efforts in bridging global health equity because they extend our reach, expertise, and outcomes. Each partner in our global network brings their unique perspectives, knowledge, capabilities, and passion for improving lives. Together, we face challenges and find solutions for people living with cancer around the world. We celebrate our partners and welcome new partnerships to expand our reach.
Partner with us
Our diverse partnerships are making an impact in the lives of cancer patients worldwide.
